Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Inclusion Criteria

• •Female
• •At least one prescription for bazedoxifene, raloxifene, or any bisphosphonate during the study inclusion period (index prescription);
• •A recoded diagnosis code of osteoporosis on or within 60 days prior to the index prescription date;
• •Age \>=45 at the date of the index prescription; and
• •At least 6-months of follow-up data in the electronic medical record system prior to the date of the index prescription